A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.

@article{Clark2001API,
  title={A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.},
  author={Wayne M. Clark and Larry R Wechsler and Luann Sabounjian and Ute E Schwiderski},
  journal={Neurology},
  year={2001},
  volume={57 9},
  pages={1595-602}
}
BACKGROUND Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. OBJECTIVE To determine the safety and efficacy of citicoline treatment in acute stroke patients. METHOD An 118-center, randomized, double-blind, efficacy trial in 899 patients compared placebo (n = 446) with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
67 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…